BrainEver
BrainEver's platform treats neurodegenerative diseases based on Homeoproteins (HPs). . Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€4—6m (Dealroom.co estimates Dec 2015.)
Company register number 810542506
Paris Île-de-France (HQ)
Financials
Estimates*
Date | Investors | Amount | Round |
---|---|---|---|
€1.0m | Early VC | ||
€2.5m | Grant | ||
N/A | Early VC | ||
Total Funding | €3.5m |
Related Content
Recent News about BrainEver
EditMore about BrainEver
EditOperator of a medical research agency intended to develop drugs for the treatment of neurodegenerative disorders. The company's services specialize in the research and development of novel therapeutics using specific proprietary proteins to treat Parkinson's, amyotrophic lateral sclerosis, and Huntington's diseases, enabling healthcare practitioners to avail of drugs while providing the required treatment efficiently.
Keywords: Pharmaceuticals and Biotechnology, Drug Research Center, Drug Research Process, Homeoprotein Administration, Medical Research Agency, Neurodegenerative Disorder, Novel Therapeutics.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.